Single Dose of Omeros’ Lead MASP-3 Inhibitor OMS906 Shows Multi-Week Blockade of the Alternative Pathway
-- Non-Human Primate Data Support Advancing to Clinic --
Single-dose administration of OMS906 to cynomolgus monkeys resulted in sustained ablation of systemic APC activity for approximately 16 days. The extent of APC ablation was comparable to that achieved by complete inhibition of factor D in vitro, indicating that OMS906 fully blocked the conversion of pro-factor D to factor D. Similar results were obtained with a number of the company’s other antibodies targeting MASP-3. No safety concerns were identified.
The primate data are consistent with recently reported results from well-established animal models in which OMS906 reduced the incidence and severity of arthritis by 86 percent (p < 0.005) and 90 percent (p < 0.01), respectively, and significantly improved the survival of PNH-like red blood cells approximately four-fold better (p = 0.029) than did a complement factor 5 (C5) inhibitor.
“The OMS906 primate data bode well for the antibody’s long-acting
inhibition of MASP-3 in patients, and the unique mechanism of action of
MASP-3 inhibition likely has significant clinical advantages over many
other alternative pathway inhibitors,” said Sir
About Omeros’ MASP-3 Inhibitor Program
The complement system plays a key role in inflammation and becomes
activated as a result of tissue damage or microbial infection. Omeros’
MASP-3 inhibitor program includes potent molecules selectively
inhibiting mannan-binding lectin-associated serine protease-3 (MASP-3),
the protein responsible for processing Factor D, which is essential for
activation of the alternative pathway of complement (APC). APC
inhibitors are thought to have preventive or therapeutic effects across
a broad range of diseases including hemolytic uremic syndrome (HUS),
atypical HUS, paroxysmal nocturnal hemoglobinuria, traumatic brain
injury, arthritis, wet age-related macular degeneration,
ischemia-reperfusion injury, transplant-related complications and other
immune-related disorders.
About
Forward-Looking Statements
This press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section 21E of
the Securities Exchange Act of 1934, which are subject to the “safe
harbor” created by those sections for such statements. All statements
other than statements of historical fact are forward-looking statements,
which are often indicated by terms such as “anticipate,” “believe,”
“could,” “estimate,” “expect,” “goal,” “intend,” “look forward to,”
“may,” “plan,” “potential,” “predict,” “project,” “should,” “will,”
“would” and similar expressions and variations thereof. Forward-looking
statements are based on management’s beliefs and assumptions and on
information available to management only as of the date of this press
release. Omeros’ actual results could differ materially from those
anticipated in these forward-looking statements for many reasons,
including, without limitation, risks associated with product
commercialization and commercial operations, unproven preclinical and
clinical development activities, regulatory oversight, intellectual
property claims, competitive developments, litigation, and the risks,
uncertainties and other factors described under the heading “Risk
Factors” in the company’s Quarterly Report on Form 10-Q filed with the
View source version on businesswire.com: http://www.businesswire.com/news/home/20161110005641/en/
Source:
Cook Williams Communications, Inc.
Jennifer Cook Williams,
360-668-3701
Investor and Media Relations
[email protected]